Austin Hospital, Melbourne Australia
17
3
3
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
11.8%
2 terminated/withdrawn out of 17 trials
77.8%
-8.7% vs industry average
12%
2 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study
Role: collaborator
Acute Kidney Injury - Epidemiology in Intensive Care Unit Patients 2: an International Multicenter Cohort Study
Role: collaborator
Inspiratory Strength and Respiratory Complications After SCI Injury
Role: collaborator
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
Role: collaborator
Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient
Role: collaborator
The SHIELD Study-silicosis
Role: collaborator
Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease
Role: collaborator
Early Intensive Hand Rehabilitation After Spinal Cord Injury
Role: collaborator
REVERSE-AKI Randomized Controlled Pilot Trial
Role: collaborator
HepATocellular Cancer Hcv Therapy Study
Role: collaborator
The Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock Trial
Role: collaborator
A Prospective Observational Study of the Expectations and Physiological Effects of Fluid Bolus Therapy
Role: collaborator
Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
Role: collaborator
Furosemide in Early Acute Kidney Injury
Role: collaborator
Does Positive Expiratory Pressure Mask Therapy Improve Recovery From Acute Exacerbations of Chronic Obstructive Pulmonary Disease?
Role: collaborator
Pulmonary Rehabilitation in Interstitial Lung Disease
Role: collaborator
Outcomes of Swallowing Rehabilitation After Stroke
Role: collaborator
All 17 trials loaded